Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 7/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179455 | 0.82 | BCL6 (0.46) | NUDT1GRM4FGFR1BCL6 | |
| SCHEMBL179505 | 0.82 | BCL6 (0.46) | NUDT1FGFR1JAK2BCL6 | |
| SCHEMBL179464 | 0.82 | BCL6 (0.46) | NUDT1FGFR1JAK2BCL6 | |
| SCHEMBL179491 | 0.82 | BCL6 (0.46) | NUDT1GRM4FGFR1BCL6 | |
| SCHEMBL179461 | 0.82 | BCL6 (0.46) | NUDT1GRM4FGFR1BCL6 | |
| SCHEMBL179356 | 0.82 | BCL6 (0.46) | NUDT1FGFR1JAK2BCL6 | |
| SCHEMBL9885018 | 0.80 | NUDT1 (0.55) | NUDT1GRM4IRAK4 | |
| SCHEMBL9884961 | 0.80 | NUDT1 (0.55) | NUDT1GRM4IRAK4 | |
| SCHEMBL179487 | 0.80 | ULK1 (0.43) | NUDT1JAK2BCL6 | |
| SCHEMBL179499 | 0.80 | ULK1 (0.43) | NUDT1JAK2BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NUDT1 791/4885GRM4 4193/4885IRAK4 770/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | NUDT1 1283/4885GRM4 4403/4885IRAK4 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.